NC
AMPH icon

nVerses Capital’s Amphastar Pharmaceuticals AMPH Stock Holding History

nVerses Capital’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-17,685
Closed -$346K – 297
2026
Q1 		$346K Buy
+17,685
New +$433K 0.31% 129
2024
Q4 		– Sell
-2,600
Closed -$126K – 45
2024
Q3 		$126K Buy
2,600
+400
+18% +$17.6K 0.06% 427
2024
Q2 		$88K Buy
2,200
+600
+38% +$24.9K 0.05% 470
2024
Q1 		$70.3K Buy
+1,600
New +$82.6K 0.17% 224

Other funds holding AMPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

nVerses Capital's AMPH Position: Q2 2026 in Review

nVerses Capital sold out of Amphastar Pharmaceuticals (AMPH) in Q2 2026, closing a stake of 17,685 shares — an estimated $346K sold.

nVerses Capital first reported a position in AMPH in Q1 2024 and held it in 4 quarters. The position peaked at $346K in Q1 2026. 162 funds tracked by Wall St. Rank hold AMPH as of Q2 2026.

  • nVerses Capital reported no remaining Amphastar Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • nVerses Capital sold 17,685 Amphastar Pharmaceuticals shares in Q2 2026, an estimated $346K.
  • nVerses Capital first reported a position in Amphastar Pharmaceuticals in Q1 2024 and held it in 4 quarters.
  • nVerses Capital's Amphastar Pharmaceuticals position peaked at $346K in Q1 2026.
  • 162 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q2 2026.

Based on nVerses Capital's 13F filing for Q2 2026, filed 4 Aug 2026.